These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 20032799)
1. The effects of raloxifene on mammographic breast density: a review of clinical trials. Pearman L; Kagan R; Arsenault J; Muram D Menopause; 2010; 17(3):654-9. PubMed ID: 20032799 [TBL] [Abstract][Full Text] [Related]
2. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. Freedman M; San Martin J; O'Gorman J; Eckert S; Lippman ME; Lo SC; Walls EL; Zeng J J Natl Cancer Inst; 2001 Jan; 93(1):51-6. PubMed ID: 11136842 [TBL] [Abstract][Full Text] [Related]
3. Primary prevention of breast cancer: new approaches. Cummings SR Maturitas; 2007 May; 57(1):39-41. PubMed ID: 17391879 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women. Jackson VP; San Martin JA; Secrest RJ; McNabb M; Carranza-Lira S; Figueroa-Casas P; Fernandes CE; Romaguera J Am J Obstet Gynecol; 2003 Feb; 188(2):389-94. PubMed ID: 12592245 [TBL] [Abstract][Full Text] [Related]
5. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS; J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858 [TBL] [Abstract][Full Text] [Related]
6. [Menopausal hormonal therapies: impact on mammographic breast density]. Boutet G; Boisserie-Lacroix M; Trillaud H J Radiol; 2004 Oct; 85(10 Pt 1):1673-86. PubMed ID: 15669560 [TBL] [Abstract][Full Text] [Related]
7. Does raloxifene therapy affect mammographic breast cancer screening in postmenopausal patients? Cirpan T; Akercan F; Itil IM; Gundem G; Bilgen I; Yucebilgin MS Eur J Gynaecol Oncol; 2006; 27(2):177-8. PubMed ID: 16620065 [TBL] [Abstract][Full Text] [Related]
8. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast. Pickar JH; Komm BS Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836 [TBL] [Abstract][Full Text] [Related]
9. Tamoxifen, mammographic density, and breast cancer prevention. Boyd NF J Natl Cancer Inst; 2011 May; 103(9):704-5. PubMed ID: 21487099 [No Abstract] [Full Text] [Related]
10. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women. Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N Menopause; 2006; 13(5):787-92. PubMed ID: 16912660 [TBL] [Abstract][Full Text] [Related]
11. Breast cancer: risk assessment and prevention. Hooks MA South Med J; 2010 Apr; 103(4):333-8. PubMed ID: 20224493 [TBL] [Abstract][Full Text] [Related]
12. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N; JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727 [TBL] [Abstract][Full Text] [Related]
13. Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia. Mosca L; Harper K; Sarkar S; O'Gorman J; Anderson PW; Cox DA; Barrett-Connor E Clin Ther; 2001 Sep; 23(9):1552-65. PubMed ID: 11589267 [TBL] [Abstract][Full Text] [Related]
14. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Eng-Wong J; Orzano-Birgani J; Chow CK; Venzon D; Yao J; Galbo CE; Zujewski JA; Prindiville S Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1696-701. PubMed ID: 18583470 [TBL] [Abstract][Full Text] [Related]
15. Biological significance of interventions that change breast density. Chlebowski RT; McTiernan A J Natl Cancer Inst; 2003 Jan; 95(1):4-5. PubMed ID: 12509389 [No Abstract] [Full Text] [Related]
16. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases]. Higuchi T; Mizunuma H Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136 [TBL] [Abstract][Full Text] [Related]
17. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women]. Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371 [TBL] [Abstract][Full Text] [Related]
19. Breast cancer chemoprevention: A service in need of menopause specialist support. Marsden J Post Reprod Health; 2017 Mar; 23(1):15-21. PubMed ID: 28081658 [No Abstract] [Full Text] [Related]
20. Low-dose transdermal estradiol induces breast density and heterogeneity changes comparable to those of raloxifene. Nielsen M; Raundahl J; Pettersen PC; Loog M; Karemore G; Karsdal MA; Christiansen C Menopause; 2009; 16(4):785-91. PubMed ID: 19322115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]